Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00057811 · ClinicalTrials.gov registry record · Phase 2
Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma
A Phase 2 study, sponsored by Children's Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 97
- Enrollment target
NCT00057811 is a Phase 2 study that has completed, run by Children's Oncology Group. The registered enrollment target is 97 participants.
The verdict
NCT00057811, a Phase 2 study, has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 97 participants
- Enrollment target
Study Summary
Phase II trial to study the effectiveness of combining rituximab and rasburicase with combination chemotherapy in treating young patients who have newly diagnosed advanced B-cell leukemia or lymphoma. Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug with rituximab may kill more cancer cells. Chemoprotective drugs such as rasburicase may protect kidney cells from the side effects of chemotherapy.
Interventions
- DRUG cyclophosphamide
- DRUG leucovorin calcium
- DRUG methotrexate
- DRUG doxorubicin hydrochloride
- DRUG rasburicase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2004-06 |
| Est. Completion | 2014-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00057811
The ClinicalTrials.gov registry entry for NCT00057811 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 97 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Oncology Group, which has 342 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00057811 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00057811 about?
NCT00057811 is a clinical study titled "Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma". Phase II trial to study the effectiveness of combining rituximab and rasburicase with combination chemotherapy in treating young patients who have newly diagnosed advanced B-cell leukemia or lymphoma. Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver can...
What is the current status of trial NCT00057811?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 97 participants. The study started on 2004-06. Estimated completion is 2014-07.
What interventions are being tested in trial NCT00057811?
The interventions under investigation include: cyclophosphamide (DRUG), leucovorin calcium (DRUG), methotrexate (DRUG), doxorubicin hydrochloride (DRUG), rasburicase (DRUG).
Who is sponsoring clinical trial NCT00057811?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.